A prognostic model based on gene expression parameters predicts a better response to bortezomib-containing immunochemotherapy in diffuse large B-cell lymphoma

Frontiers in Oncology

Oncology

Miguel Cid López¹  Andrés Peleteiro Raíndo¹  Marta Sonia González Pérez¹  Adrián Mosquera Orgueira¹  Jose Ángel Díaz Arías¹  Juan Carlos Vallejo Llamas¹  Victor Portela Piñeiro¹  Máximo Francisco Fraga Rodríguez¹  José Luis Bello López¹  Rocio Serrano Martín¹  Laura Bao Pérez¹  Manuel Mateo Pérez Encinas¹ 

[1] University Hospital of Santiago de Compostela, Servizo Galego de Saúde (SERGAS), Santiago de Compostela, Spain;Health Research Institute of Santiago de Compostela, Santiago de Compostela, Spain;

关键词: machie learning;    DLBCL - diffuse large B cell lymphoma;    bortezomib;    R-CHOP;    lymphoma;    genomics;    gene expression;   

DOI  :  10.3389/fonc.2023.1157646

 received in 2023-02-02, accepted in 2023-04-17,  发布年份 2023

来源: Frontiers

【 摘 要 】

Diffuse Large B-cell Lymphoma (DLBCL) is the most common type of aggressive lymphoma. Approximately 60% of fit patients achieve curation with immunochemotherapy, but the remaining patients relapse or have refractory disease, which predicts a short survival. Traditionally, risk stratification in DLBCL has been based on scores that combine clinical variables. Other methodologies have been developed based on the identification of novel molecular features, such as mutational profiles and gene expression signatures. Recently, we developed the LymForest-25 profile, which provides a personalized survival risk prediction based on the integration of transcriptomic and clinical features using an artificial intelligence system. In the present report, we studied the relationship between the molecular variables included in LymForest-25 in the context of the data released by the REMoDL-B trial, which evaluated the addition of bortezomib to the standard treatment (R-CHOP) in the upfront setting of DLBCL. For this, we retrained the machine learning model of survival on the group of patients treated with R-CHOP (N=469) and then made survival predictions for those patients treated with bortezomib plus R-CHOP (N=459). According to these results, the RB-CHOP scheme achieved a 30% reduction in the risk of progression or death for the 50% of DLBCL patients at higher molecular risk (p-value 0.03), potentially expanding the effectiveness of this treatment to a wider patient population as compared with other previously defined risk groups.

【 授权许可】

Unknown   
Copyright © 2023 Mosquera Orgueira, Díaz Arías, Serrano Martín, Portela Piñeiro, Cid López, Peleteiro Raíndo, Bao Pérez, González Pérez, Pérez Encinas, Fraga Rodríguez, Vallejo Llamas and Bello López